October 30, 2026 Type 1 diabetes briefing: trials, device safety, and research signals
A daily Type1Cure briefing built from current official and public source pulls, with each item labeled by source, evidence class, and family relevance.
The short version
The October 30, 2026 feed is strongest in three lanes: device safety, recruiting studies, and recent research records. Type1Cure treats safety and trial records as higher-priority signals because they can affect what a family may need to check, ask, or watch next.
This is not a medical recommendation. It is a source map and plain-English triage layer designed to help families decide what deserves a closer look with their care team.
Signals in the feed
- Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. — RECRUITING, PHASE2, PHASE3. Interventions: Semaglutide, Placebo. Locations: Montreal, Quebec, Canada. The goal of this 24 week double-blinded, randomized, parallel controlled clinical trial is to learn how semaglutide a...Source
- Medtronic MiniMed, Inc.: Generic Name: MiniMed Go App Generic Name: MiniMed Go App Model/Catalog Number: MMT-8600 (iOS), MMT-8601 (Android) Software Version: Software version 1.2.1 Product Description: Th... — A software defect in which existing users who had previously configured and enabled the long-acting dose reminder feature in version 1.2.0 or earlier experienced failure of the long-acting dose reminder after updating t...Source
- Medtronic MiniMed, Inc.: Brand Name: MiniMed Flex Product Name: MiniMed Flex Insulin Pump Model/Catalog Numbers: MMT-8062; MMT-8072 Product Description: The MiniMed Flex pump is an alternate controller en... — Some MiniMed Flex insulin pumps were released with missing (i.e., devices with no result or abort test results are presumed to have failed) or failed verification test results in one or more of 9 functional tests. The u...Source
- Tandem Diabetes Care, Inc.: Brand Name: Tandem t:slim mobile application Product Name: t:slim Mobile Application, iOS Model/Catalog Number: iOS software version 2.13 Software Version: iOS software version 2.... — A beta (early-release) version of the iOS application, version 2.13 (TestFlight) had a software issue preventing successful pairing of the t:slim application with Abbott FreeStyle Libre 3 Plus (FSL3P) continuous glucose...Source
- Feasibility and Effectiveness of Tele-diabetes Remote System on Glycemic Control and Quality of Life of Children and Youth With Type 1 Diabetes — RECRUITING, NA. Interventions: Tele-diabetes Remote System. Locations: Ramat Gan, Israel. The goal of this clinical trial is to examine the feasibility and effectiveness of a tele-diabetes remote monitoring system on ma...Source
- The iLet Experience Study — RECRUITING. Interventions: iLet Dosing Decision Software. Locations: Irvine, California, United States. A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decisio...Source
- Safety Evaluation of MODI, an Insulin Titration Algorithm, in Adults With Diabetes — RECRUITING, NA. Interventions: MODI Algorithm. Locations: Baltimore, Maryland, United States | Detroit, Michigan, United States | Albany, New York, United States. A 13-week multi-center single-arm trial, preceded by a 2...Source
How to use this briefing
Start with the evidence label. Official registry and regulator records are not the same thing as advice, but they are stronger source material than a repost, rumor, or promotional headline.
For trials, check eligibility, location, burden, intervention, and contact details at the original registry. For device safety, check exact product names, models, lot numbers, software versions, and manufacturer instructions.
This article is an evidence-labeled information brief, not medical advice. Use the linked source records and your care team before making treatment decisions.